Kavita Patel

CIK 1670683 · last filed 2026-04-28

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$320.1K

Companies

4

Total Filings

40

Lifetime Open-Market Net

-$8.34M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Arcellx, Inc. (ACLX) Delisted Director 0 $115.07 $0 -$8.34M 24 2026-04-28
SLQT Director 363,214 $0.88 $320.1K $0 7 2025-11-13
Sigilon Therapeutics, Inc. (SGTX) Delisted Director $22.47 $0 4 2023-08-11
TESARO, Inc. (TSRO) Delisted Director 0 $0 5 2019-01-22

Recent Filings · Page 4 of 4

40 filings
Form 4 transactions across all companies, newest first.
Filed Symbol Action Net Shares Net $ Link
2022-02-07 Arcellx, Inc. (ACLX) Delisted Grant (A) $0 EDGAR
2021-12-09 SLQT Exer (M) +4,719 $0 EDGAR
2021-11-15 SLQT Grant (A) $0 EDGAR
2021-06-28 Sigilon Therapeutics, Inc. (SGTX) Delisted Grant (A) $0 EDGAR
2020-12-11 SLQT Grant (A) $0 EDGAR
2019-01-22 TESARO, Inc. (TSRO) Delisted Mixed −2,757 -$206.8K EDGAR
2018-06-05 TESARO, Inc. (TSRO) Delisted Grant (A) +1,226 $0 EDGAR
2017-06-05 TESARO, Inc. (TSRO) Delisted Grant (A) +368 $0 EDGAR
2016-06-03 TESARO, Inc. (TSRO) Delisted Grant (A) +1,163 $0 EDGAR
2016-04-04 TESARO, Inc. (TSRO) Delisted Grant (A) $0 EDGAR
Showing 3140 of 40
Page 4 of 4
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.